Ardea Biosciences, Inc. (NASDAQ: RDEA) is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases. The Company’s most advanced clinical-stage product candidates include RDEA594 for the chronic management of hyperuricemia and gout; BAY 86-9766 for the treatment of cancer; and RDEA806 for the treatment of HIV. For further information, visit the Company’s Web site at www.ardeabiosciences.com.

Noble Financial, a research driven, full-service investment banking boutique, is as discriminating with its invitations to institutional investors as it is with the companies invited to present. Rather than just focusing on crowding the conference floor, Noble Financial carefully invites a smaller audience of investors with a large appetite for the companies presenting; quality always trumps quantity. For more information or to view webcasts of today’s presentations, visit www.noblefcm.com.

Let us hear your thoughts below: